clinical trial · NCT07028489
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
N-Power Medicine·—·recruiting·n = 130
Non Small Cell Lung Cancer
brief summary
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
started
Jun 5, 2025
primary completion
Dec 1, 2028
completion
Apr 1, 2029
last updated
Mar 3, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol